Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
Barr, Paul M. (University of Rochester Medical Center, USA)
Owen, Carolyn (University of Calgary, Canada)
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland)
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy)
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel)
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA)
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK)
Dearden, Claire (The Royal Marsden Hospital, London, UK)
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland)
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit))
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China)
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium)
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA)
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA)
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA)
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA)
Kipps, Thomas J (University of California San Diego. Moores Cancer Center)
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)

Data:	2022
Resum:	What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. What were the results? Researchers looked at 269 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received any treatment for their CLL/SLL. Study participants were randomly divided into two groups: 136 participants received treatment with a drug called ibrutinib, and 133 participants received treatment with a drug called chlorambucil. Participants in the study were treated and followed for up to 8 years, with results showing that more participants who took ibrutinib (59%) were alive without worsening of their disease at 7 years after starting treatment than participants who took chlorambucil (9%). Almost half of the participants (42%) were able to stay on ibrutinib treatment for up to 8 years. What do the results of the study mean? In people with CLL or SLL, more participants who were taking ibrutinib were alive without worsening of their disease after 7 years compared with participants who took chlorambucil.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Publicat a:	Future oncology (London, England), Vol. 18 Núm. 37 (january 2022) , ISSN 1744-8301

DOI: 10.2217/fon-2022-0898

11 p, 1.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats
Articles > Ressenyes